Polascik TJ - Search Results

1

Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.

Ahmed HU, Akin O, Coleman JA, Crane S, Emberton M, Goldenberg L, Hricak H, Kattan MW, Kurhanewicz J, Moore CM, Parker C, Polascik TJ, Scardino P, van As N, Villers A; Transatlantic Consensus Group on Active Surveillance and Focal Therapy for Prostate Cancer (appendix). Ahmed HU, et al. Among authors: polascik tj. BJU Int. 2012 Jun;109(11):1636-47. doi: 10.1111/j.1464-410X.2011.10633.x. Epub 2011 Nov 11. BJU Int. 2012. PMID: 22077593 Free PMC article.

2

Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.

Sun L, Moul JW, Hotaling JM, Rampersaud E, Dahm P, Robertson C, Fitzsimons N, Albala D, Polascik TJ. Sun L, et al. Among authors: polascik tj. BJU Int. 2007 Apr;99(4):753-7. doi: 10.1111/j.1464-410X.2006.06682.x. Epub 2007 Jan 19. BJU Int. 2007. PMID: 17244286

3

Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy.

Schroeck FR, Sun L, Freedland SJ, Albala DM, Mouraviev V, Polascik TJ, Moul JW. Schroeck FR, et al. Among authors: polascik tj. BJU Int. 2008 Jul;102(1):28-32. doi: 10.1111/j.1464-410X.2008.07607.x. Epub 2008 Apr 2. BJU Int. 2008. PMID: 18384634

4

Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy.

Polascik TJ, Mayes JM, Schroeck FR, Sun L, Madden JF, Moul JW, Mouraviev V. Polascik TJ, et al. Cancer. 2009 May 15;115(10):2104-10. doi: 10.1002/cncr.24258. Cancer. 2009. PMID: 19288576 Free article.

5

Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy.

Kimura M, Mouraviev V, Tsivian M, Mayes JM, Satoh T, Polascik TJ. Kimura M, et al. Among authors: polascik tj. BJU Int. 2010 Jan;105(2):191-201. doi: 10.1111/j.1464-410X.2009.08715.x. Epub 2009 Jul 2. BJU Int. 2010. PMID: 19583717 Review.

6

Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended.

Tsivian M, Kimura M, Sun L, Mouraviev V, Mayes JM, Polascik TJ. Tsivian M, et al. Among authors: polascik tj. BJU Int. 2010 Apr;105(8):1089-92. doi: 10.1111/j.1464-410X.2009.08904.x. Epub 2009 Oct 10. BJU Int. 2010. PMID: 19818078

7

Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans.

Caire AA, Sun L, Polascik TJ, Albala DM, Moul JW. Caire AA, et al. Among authors: polascik tj. BJU Int. 2010 Oct;106(8):1157-60. doi: 10.1111/j.1464-410X.2010.09340.x. BJU Int. 2010. PMID: 20367635

8

Prostate biopsy in selecting candidates for hemiablative focal therapy.

Tsivian M, Hruza M, Mouraviev V, Rassweiler J, Polascik TJ. Tsivian M, et al. Among authors: polascik tj. J Endourol. 2010 May;24(5):849-53. doi: 10.1089/end.2009.0473. J Endourol. 2010. PMID: 20370327

9

Focal therapy for prostate cancer: possibilities and limitations.

Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ, Brewster S. Eggener S, et al. Among authors: polascik tj. Eur Urol. 2010 Jul;58(1):57-64. doi: 10.1016/j.eururo.2010.03.034. Epub 2010 Mar 26. Eur Urol. 2010. PMID: 20378241 Review.

10

Focal cryotherapy for prostate cancer.

Tsivian M, Polascik TJ. Tsivian M, et al. Among authors: polascik tj. Curr Urol Rep. 2010 May;11(3):147-51. doi: 10.1007/s11934-010-0100-1. Curr Urol Rep. 2010. PMID: 20425620 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

352 results

Search Page